Source:Medical Hypotheses
Author(s): Ilan Gruenwald, Ege Can Serefoglu, Tal Gollan, Shmuel Springer, Gideon Meiry, Appel Boaz, Shechter Arik
Premature ejaculation (PE) is a very common and disturbing sexual dysfunction in men, associated with detrimental psychological, physical and social effects. Approximately 20-30% of sexually active men suffer from PE [1–3]. Although this dysfunction has been widely investigated, its pathophysiology still remains unclear. Today, there is only one oral compound, which has been specifically developed for the pharmaceutical treatment of PE, Dapoxetine. Although it has been approved by the European Medical Agency (EMEA), Dapoxetine has not been approved by the U.S. Food and Drug Administration (FDA), due to its controversial efficacy and safety [4,5]. Therefore, the treatment of PE continues to be a major area of medical research.
http://ift.tt/2xBM0kY
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου